Sheffield Teaching Hospitals Nhs Foundation Trust

The UK DANTE phase III trial found that 80.2% of patients who stopped immunotherapy after 12 months maintained disease control, compared to 87.6% who continued treatment for two years or more.

A 24-year-old woman from York has become one of the first patients worldwide to participate in the FORTITUDE trial, a pioneering gene therapy study for facioscapulohumeral muscular dystrophy (FSHD).

• A new Phase 3 trial called FINESSE will evaluate whether finasteride can improve adherence to active surveillance in men with low and intermediate-risk prostate cancer. • The study will enroll 550 men across eight sites, randomizing patients to receive either standard active surveillance alone or with daily finasteride for two years. • The trial aims to address poor long-term compliance with active surveillance, with outcomes tracked for up to 10 years including disease progression, mortality, and quality of life measures.

The TRICEPS trial is evaluating a portable device that uses electrical pulses to stimulate the vagus nerve via an earpiece, aiming to improve arm function in stroke patients.

An electronic tool, the stroke trial tracker, has been developed to streamline the screening and management of stroke patients for clinical trial eligibility.